Jim Simons Compugen LTD Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Compugen LTD stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,395,272 shares of CGEN stock, worth $2.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,395,272

Previous 1,277,200 9.24%

Holding current value

$2.12 Million

Previous $1.95 Million 4.25%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$1.46 - $2.57 $172,385 - $303,445	118,072 Added 9.24%	1,395,272 $2.04 Million
Q4 2024 Feb 13, 2025	SELL	$1.41 - $1.93 $13,959 - $19,107	-9,900 Reduced 0.77%	1,277,200 $1.95 Million
Q3 2024 Nov 13, 2024	SELL	$1.56 - $2.1 $2,808 - $3,780	-1,800 Reduced 0.14%	1,287,100 $2.33 Million
Q2 2024 Aug 09, 2024	SELL	$1.68 - $2.52 $13,608 - $20,412	-8,100 Reduced 0.62%	1,288,900 $2.17 Million
Q1 2024 May 13, 2024	BUY	$1.75 - $2.95 $307,825 - $518,905	175,900 Added 15.69%	1,297,000 $3.35 Million
Q4 2023 Feb 13, 2024	BUY	$0.53 - $2.0 $14,204 - $53,600	26,800 Added 2.45%	1,121,100 $2.22 Million
Q3 2023 Nov 14, 2023	BUY	$0.88 - $1.31 $49,192 - $73,229	55,900 Added 5.38%	1,094,300 $1.02 Million
Q2 2023 Aug 11, 2023	BUY	$0.57 - $1.38 $57,170 - $138,414	100,300 Added 10.69%	1,038,400 $1.18 Million
Q1 2023 May 12, 2023	SELL	$0.68 - $1.11 $228,252 - $372,589	-335,666 Reduced 26.35%	938,100 $659,000
Q4 2022 Feb 13, 2023	SELL	$0.58 - $1.2 $637,351 - $1.32 Million	-1,098,882 Reduced 46.31%	1,273,766 $912,000
Q3 2022 Nov 14, 2022	BUY	$0.66 - $2.32 $707,900 - $2.49 Million	1,072,576 Added 82.5%	2,372,648 $1.56 Million
Q2 2022 Aug 12, 2022	BUY	$1.57 - $3.33 $773,471 - $1.64 Million	492,657 Added 61.02%	1,300,072 $2.41 Million
Q1 2022 May 13, 2022	BUY	$2.76 - $4.64 $1.59 Million - $2.68 Million	577,515 Added 251.2%	807,415 $2.6 Million
Q4 2021 Feb 11, 2022	SELL	$4.09 - $7.16 $1.81 Million - $3.17 Million	-442,400 Reduced 65.8%	229,900 $989,000
Q3 2021 Nov 12, 2021	SELL	$5.8 - $8.02 $680,920 - $941,548	-117,400 Reduced 14.87%	672,300 $4.01 Million
Q2 2021 Aug 13, 2021	BUY	$6.87 - $9.16 $2.64 Million - $3.53 Million	384,884 Added 95.08%	789,700 $6.54 Million
Q1 2021 May 13, 2021	BUY	$7.67 - $13.77 $3.1 Million - $5.57 Million	404,816 New	404,816 $3.48 Million
Q3 2020 Nov 13, 2020	SELL	$14.16 - $19.45 $455,952 - $626,290	-32,200 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$6.97 - $17.12 $3.02 Million - $7.41 Million	-432,700 Reduced 93.07%	32,200 $484,000
Q1 2020 May 14, 2020	SELL	$5.79 - $11.83 $1.52 Million - $3.1 Million	-262,100 Reduced 36.05%	464,900 $3.38 Million
Q4 2019 Feb 13, 2020	BUY	$3.9 - $6.16 $344,760 - $544,544	88,400 Added 13.84%	727,000 $4.33 Million
Q3 2019 Nov 13, 2019	BUY	$3.01 - $4.49 $243,207 - $362,792	80,800 Added 14.49%	638,600 $2.7 Million
Q2 2019 Aug 12, 2019	BUY	$2.8 - $4.14 $267,400 - $395,369	95,500 Added 20.66%	557,800 $2.14 Million
Q1 2019 May 14, 2019	BUY	$2.35 - $4.19 $257,795 - $459,643	109,700 Added 31.11%	462,300 $1.91 Million
Q4 2018 Feb 13, 2019	BUY	$2.17 - $3.8 $765,142 - $1.34 Million	352,600 New	352,600 $765,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

16.3M

Call Options Held

28.7K

Put Options Held

48.3K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $132M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account